ts-ims

Rare Pediatric Diseases

A legal classification under the U.S. FD&C Act for serious or life-threatening diseases affecting fewer than 200,000 people in the U.S., primarily from birth to age 18. It is crucial for pharmaceutical firms seeking Priority Review Vouchers (PRVs) to expedite drug approval, impacting R&D strategy and market access risk.

Curated by Winners Consulting Services Co., Ltd.

Putting this into practice

Winners Consulting helps organizations turn this concept into workable policies, processes and audit readiness.

Need help with compliance implementation?

Request Free Assessment